Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Penny L Moore

Showing results (11-20 of 214) with videos related to

Pageof 22
Sort By:
The New England Journal of Medicine|April 7, 2022
Omicron - Decoupling Infection from Severe DiseasePenny L Moore, Lindsey R Baden
AIDS (London, England)|December 4, 2004
Predicted genotypic resistance to the novel entry inhibitor, BMS-378806, among HIV-1 isolates of subtypes A to GPenny L Moore, Tonie Cilliers, Lynn Morris
Journal of the International AIDS Society|May 15, 2026
How Vaccinating People Living With HIV May Guide bNAb‑Based VaccinesPenny L Moore, Leonidas Stamatatos, Alexandra Trkola
Expert Opinion on Therapeutic Targets|April 29, 2020
Targeting the N332-supersite of the HIV-1 envelope for vaccine designThandeka Moyo, Dale Kitchin, Penny L Moore
The Lancet. HIV|December 7, 2023
Super early treatment for HIV acquired in uteroPhilippe Van de Perre, Penny L Moore
Trends in Microbiology|January 10, 2015
Virological features associated with the development of broadly neutralizing antibodies to HIV-1Penny L Moore, Carolyn Williamson, Lynn Morris
Current Opinion in HIV and AIDS|March 26, 2014
Development of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infectionCynthia A Derdeyn, Penny L Moore, Lynn Morris
Current Opinion in HIV and AIDS|March 12, 2015
HIV broadly neutralizing antibody targetsConstantinos Kurt Wibmer, Penny L Moore, Lynn Morris
Current Opinion in HIV and AIDS|September 7, 2023
Anticipating HIV viral escape - resistance to active and passive immunizationCarolyn Williamson, Rebecca M Lynch, Penny L Moore
Current Opinion in HIV and AIDS|January 6, 2010
Specificity of the autologous neutralizing antibody responsePenny L Moore, Elin S Gray, Lynn Morris
Pageof 22

Showing results (11-20 of 214) with videos related to

Sort By:
Pageof 22
The New England Journal of Medicine|April 7, 2022
Omicron - Decoupling Infection from Severe DiseasePenny L Moore, Lindsey R Baden
AIDS (London, England)|December 4, 2004
Predicted genotypic resistance to the novel entry inhibitor, BMS-378806, among HIV-1 isolates of subtypes A to GPenny L Moore, Tonie Cilliers, Lynn Morris
Journal of the International AIDS Society|May 15, 2026
How Vaccinating People Living With HIV May Guide bNAb‑Based VaccinesPenny L Moore, Leonidas Stamatatos, Alexandra Trkola
Expert Opinion on Therapeutic Targets|April 29, 2020
Targeting the N332-supersite of the HIV-1 envelope for vaccine designThandeka Moyo, Dale Kitchin, Penny L Moore
The Lancet. HIV|December 7, 2023
Super early treatment for HIV acquired in uteroPhilippe Van de Perre, Penny L Moore
Trends in Microbiology|January 10, 2015
Virological features associated with the development of broadly neutralizing antibodies to HIV-1Penny L Moore, Carolyn Williamson, Lynn Morris
Current Opinion in HIV and AIDS|March 26, 2014
Development of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infectionCynthia A Derdeyn, Penny L Moore, Lynn Morris
Current Opinion in HIV and AIDS|March 12, 2015
HIV broadly neutralizing antibody targetsConstantinos Kurt Wibmer, Penny L Moore, Lynn Morris
Current Opinion in HIV and AIDS|September 7, 2023
Anticipating HIV viral escape - resistance to active and passive immunizationCarolyn Williamson, Rebecca M Lynch, Penny L Moore
Current Opinion in HIV and AIDS|January 6, 2010
Specificity of the autologous neutralizing antibody responsePenny L Moore, Elin S Gray, Lynn Morris
Pageof 22